688331 荣昌生物
交易中 04-16 14:47:10
资讯
新帖
简况
港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%
智通财经 · 09:01
港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%
智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率
智通财经 · 07:41
智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率
荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款
智通财经 · 04-15 16:46
荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款
港股创新药板块午后持续走高，荣昌生物涨近10%
每日经济新闻 · 04-15 13:10
港股创新药板块午后持续走高，荣昌生物涨近10%
4月13日荣昌生物涨7.98%，万家行业优选LOF基金重仓该股
证券之星 · 04-13 16:13
4月13日荣昌生物涨7.98%，万家行业优选LOF基金重仓该股
港股异动 | 荣昌生物(09995)涨超4% 维迪西妥单抗一线治疗HER2表达尿路上皮癌获批国内上市
智通财经 · 04-13
港股异动 | 荣昌生物(09995)涨超4% 维迪西妥单抗一线治疗HER2表达尿路上皮癌获批国内上市
【机构调研记录】九泰基金调研荣昌生物
证券之星 · 04-13
【机构调研记录】九泰基金调研荣昌生物
智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧
智通财经 · 04-13
智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧
荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌
美股速递 · 04-10
荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌
荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入
证券日报 · 04-10
荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入
荣昌生物：维迪西妥单抗新适应症获批准
每日经济新闻 · 04-10
荣昌生物：维迪西妥单抗新适应症获批准
荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%
证券之星 · 04-07
荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%
每周股票复盘：荣昌生物（688331）双抗ADC药物获临床试验批准
证券之星 · 04-05
每周股票复盘：荣昌生物（688331）双抗ADC药物获临床试验批准
中金：维持荣昌生物(09995)跑赢行业评级 上调目标价至133.7港元
智通财经 · 04-03
中金：维持荣昌生物(09995)跑赢行业评级 上调目标价至133.7港元
口服减重新突破，每日一粒告别针头！礼来口服GLP1药在美获批
新浪基金 · 04-03
口服减重新突破，每日一粒告别针头！礼来口服GLP1药在美获批
荣昌生物（688331）披露双抗ADC药物RC288获临床试验批准通知书，4月2日股价上涨4.12%
证券之星 · 04-02
荣昌生物（688331）披露双抗ADC药物RC288获临床试验批准通知书，4月2日股价上涨4.12%
盈利转正、BD落地，荣昌生物全球化布局走到哪一步？
21世纪经济报道 · 04-02
盈利转正、BD落地，荣昌生物全球化布局走到哪一步？
荣昌生物双特异性抗体偶联药物RC288注射液获中国药监局临床试验批准
美股速递 · 04-01
荣昌生物双特异性抗体偶联药物RC288注射液获中国药监局临床试验批准
荣昌生物(688331.SH)：双抗ADC药物注射用RC288获得药物临床试验批准通知书
智通财经 · 04-01
荣昌生物(688331.SH)：双抗ADC药物注射用RC288获得药物临床试验批准通知书
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 指盈亏平衡可期
金吾财讯 · 03-31
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 指盈亏平衡可期
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":153.24,"timestamp":1776322030000,"preClose":149,"halted":0,"volume":10843565,"delay":0,"changeRate":0.0285,"floatShares":163000000,"shares":564000000,"eps":5.1157,"marketStatus":"交易中","change":4.24,"latestTime":"04-16 14:47:10","open":148,"high":156.79,"low":144.01,"amount":1653000000,"amplitude":0.0858,"askPrice":153.24,"askSize":2,"bidPrice":153.23,"bidSize":10,"shortable":0,"etf":0,"ttmEps":5.1157,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776322800000},"marketStatusCode":2,"adr":0,"adjPreClose":149,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776303000000,1776310200000],[1776315600000,1776322800000]],"highLimit":163.9,"lowLimit":134.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":23.31,"roa":"--","peRate":29.954845,"roe":"24.87%","epsLYR":1.29,"committee":-0.811321,"marketValue":86501000000,"turnoverRate":0.0665,"status":0,"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":117.4,"timestamp":1776322017954,"preClose":118.3,"halted":0,"volume":3924294,"delay":0,"premium":"-33.32"},"floatMarketCap":24992000000},"requestUrl":"/m/hq/s/688331/wiki","defaultTab":"wiki","newsList":[{"id":"2627254292","title":"港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627254292","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627254292?lang=zh_cn&edition=full","pubTime":"2026-04-16 09:01","pubTimestamp":1776301266,"startTime":"0","endTime":"0","summary":"【重大事项】宁德时代(03750)拟投资 300 亿元设立全资子公司 打造新能源矿产平台美格智能(03268)拟投资3亿元于AI研发及先进制造产业项目并签署投资协议力勤资源(02245)：印尼镍矿政策变动不影响正常经营 与合作伙伴保持良好合作关系确保Obi项目稳定运行中远海能(01138)拟10.18亿元建造两艘巴拿马型原油轮荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0169518387.USD","LU1328277881.USD","LU2580892789.USD","LU1064131003.USD","LU0039217434.USD","BK1523","LU0011963245.USD","LU0593848301.USD","81810","LU0348814723.USD","LU1981816686.USD","LU2348773727.SGD","601111","BK4141","LU0072913022.USD","LU0326948709.USD","LU0047713382.USD","LU2087589342.USD","LU1023057109.AUD","002352","03750","LU2477742899.HKD","300750","IE00B3M56506.USD","LU0165289439.USD","LU1282648689.USD","LU2360107325.USD","LU0871576103.HKD","LU1323998911.USD","LU0516422952.EUR","LU0880133367.SGD","HK0000181138.USD","HK0000181112.HKD","LU0327786744.USD","LU1255011170.USD","HXXD.SI","BK4585","LU0611395673.USD","IE00B5MMRT66.SGD","LU0106252389.USD","LU0140636845.USD","LU0605514214.HKD","LU2249611893.SGD","LU0463099449.HKD","LU2476274720.SGD","LU1868837565.USD","06656","LU1515016050.SGD","LU0540923850.HKD","SG9999002828.SGD","LU0449515922.USD","LU2045819591.USD","LU0164865239.USD","LU0469268626.HKD","IE00BPRC5H50.USD","LU0449509016.USD","LU0048580855.USD","LU2424517915.HKD","LU0823426308.USD","LU0502904849.HKD","LU0823437842.USD","LU2238339852.HKD","LU0302445910.USD","LU0828237940.HKD","LU0029875118.USD","600026","LU0164880469.USD","LU0823414478.USD","LU0348735423.USD","LU0328353924.USD","LU0348805143.USD","LU1481107354.HKD","LU1769817179.HKD","LU0456827905.SGD","600115","LU1152091754.HKD","LU1048588211.SGD","LU1770034418.SGD","LU1813983027.USD","LU1251922891.USD","LU0124384867.USD","LU0505663152.USD","BK1607","LU0823426480.USD","LU0054450605.USD","IE00B8L5B284.USD","LU1807302812.USD","LU1719994722.HKD","LU1102505929.USD","LU2294711713.HKD","02245","LU0359201885.HKD","LU0828237510.HKD","LU0821914370.USD","LU1242518857.USD","LU2348774022.SGD","LU0651946864.USD","BK1575","LU0405327494.USD","LU0348827113.USD","LU1720050803.USD","00753","LU0823041008.USD","LU0211977185.USD","601898","BK1502","002881","LU0214875030.USD","LU2226246903.HKD","IE0034224299.USD","06936","LU0370786039.SGD","BK1166","LU0307460666.USD","LU0572944931.SGD","LU1781817850.SGD","SG9999000459.SGD","SG9999001903.USD","LU2298064838.USD","LU0594300179.USD","LU0235996351.USD","LU0531971595.HKD","LU0516423174.USD","LU1770036033.HKD","LU0143863198.USD","LU0405327148.USD","LU2257852520.SGD","LU1997245094.SGD","LU2506952410.USD","LU0106959298.USD","01177","LU2097828474.EUR","IE0003851619.USD","LU0261950470.USD","LU1794554557.SGD","603906","LU0043850808.USD","LU1808992512.USD","LU2148510915.USD","00670","LU1861219969.SGD","LU0634319403.HKD","LU1880383440.USD","LU2125910500.SGD","LU0823414551.USD","LU2289578879.USD","LU0048575426.USD","IE00BZ199S13.USD","LU1861214812.USD","BK1618","LU0797268264.HKD","LU1820825898.SGD","03908","LU1064130708.USD","LU2580892862.HKD","LU0326950275.SGD","BK1535","LU0192582467.USD","XIACY","LU0441854154.USD","LU1188198961.HKD","LU0269904917.USD","BK4519","LU1997245177.USD","LU0823397103.USD","LU1997244956.HKD","LU1105468828.SGD","LU0143863784.USD","LU2328871848.SGD","LU2778985437.USD","SG9999002463.SGD","LU2097828631.EUR","LU0259732245.USD","LU0823040885.USD","02465","LU0320764599.SGD","02186","LU3063872942.SGD","LU2242644610.SGD","LU0455707207.USD","LU1051769294.HKD","LU0348816934.USD","LU0320764755.SGD","LU2357125470.USD","LU0181495838.USD","LU1242518931.SGD","LU0417516902.SGD","LU1152091168.USD","LU0117841782.USD","LU0128522157.USD","LU2399975544.HKD","LU0828238088.HKD","LU1939255532.USD","LU0417516738.SGD","LU1146622755.USD","LU0048388663.USD","IE00B543WZ88.USD","LU0067412154.USD","SBHMY","LU0650527681.SGD","LU0456846285.SGD","CCOZY","LU2153591404.USD","LU1961090484.USD","LU0823397285.USD","LU1934453819.USD","LU2097828557.USD","LU0359202008.SGD","LU0499858438.USD","BK1521","LU0823413587.USD","SGXZ49509284.SGD","LU1039395188.USD","00300","LU1008478684.HKD","LU0607220059.USD","LU0979878070.USD","LU2476274308.USD","HK0000165453.HKD","LU0254981946.USD","LU1769817096.USD","IE0032431581.USD","SGXZ81163826.USD","LU2506952253.HKD","01093","LU1102505762.USD","LU0724618433.USD","BK1506","LU0231483743.USD","LU0700851271.USD","LU1303224171.USD","IE00B8HQ1Z84.USD","SG9999014674.SGD","LU0675040207.SGD","LU1048596156.SGD","IE00BD6J9T35.USD","BK1589","LU2506952337.HKD","LU0052750758.USD","BK1615","LU0149721374.USD","LU2298322129.HKD","LU0594300419.USD","LU0359201612.USD","LU0051755006.USD","SG9999001689.USD","HK0000286598.CNH","LU0244354667.USD","LU0708995583.HKD","LU1880383366.USD","SG9999003461.SGD","LU0499858602.USD","LU1051768304.USD","LU1831875114.USD","LU2495084118.USD","LU1868838027.USD","LU0918141887.USD","LU0561508036.HKD","BK4588","06613","LU0314109678.HKD","LU0516423091.SGD","LU0516422440.USD","BK1193","IE00B29SXG58.USD","LU0588546209.SGD","BK1610","01138","LU0918141705.HKD","LU0049853897.USD","LU0501845795.SGD","02556","03268","LU0106259558.USD","LU2506951792.HKD","FXCNY","LU0312595415.SGD","LU1979443071.USD","BK1116","LU1721428347.USD","IE0003795394.USD","LU0345775950.USD","LU1960683339.HKD","LU0516422366.SGD","BK0224","LU1655091616.SGD","LU2125910849.SGD","LU0543330483.HKD","000333","LU0107464264.USD","08279","LU0823038988.USD","SG9999001846.SGD","LU0509642566.USD","LU2449936058.SGD","688331","LU0823039010.USD","300433","BK1149","LU0164872284.USD","LU0149534421.HKD","LU0228659784.USD","01898","LU1993786604.SGD","LU2097828714.EUR","LU0084288322.USD","LU0531970944.HKD","MIUmain","LU2039709279.SGD","LU2153592121.USD","LU2152927971.USD","SG9999000327.SGD","BK4526","LU0072462343.USD","09995","LU0345776255.USD","LU2097828805.USD","01810","02038","02298","LU0348825331.USD","LU0251143458.SGD","601995","LU0651947912.USD","SG9999001093.SGD","EVS.SI","LU0672654166.SGD","LU0132412106.USD","LU0210526637.USD","LU1969619763.USD","LU1580142542.USD","LU1978683503.SGD","LU0188438112.USD","LU0823413660.USD","LU2294711473.HKD","LU2275660780.HKD","LU1956131251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627256069","title":"智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率","url":"https://stock-news.laohu8.com/highlight/detail?id=2627256069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627256069?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:41","pubTimestamp":1776296486,"startTime":"0","endTime":"0","summary":"探索词元交易等新型交易模式，构建以词元为基础，可量化、可定价的数据集价值体系。将进出口银行的境外贷款杠杆率由3上调至3.5。截至收盘，暗盘交易显示报价578港元，较招股价324.2港元上涨78.29%，每手100股，不计手续费，每手赚25380港元。归属于上市公司股东的净利润为207","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06656","LU2328871848.SGD","LU1152091168.USD","02245","BK1147","09995","03750","LU1008478684.HKD","LU1807302812.USD","LU0880133367.SGD","LU0359202008.SGD","01177","LU1993786604.SGD","601995","SBHMY","BK4585","LU0359201885.HKD","08279","300750","03908","BK4588","BK1564","LU1023057109.AUD","SG9999002828.SGD","BK1190","BK1574","BK1583","LU0359201612.USD","LU1960683339.HKD","BK1161","LU1152091754.HKD","BK1610","LU0067412154.USD","BK1516","BK1501","BK1116","688331","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627340291","title":"荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2627340291","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627340291?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:46","pubTimestamp":1776242798,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，于2026年1月12日，本公司与艾伯维就RC148签署独家授权许可协议，该协议于2026年3月10日生效。根据协议，艾伯维将获得RC148在大中华区以外地区的开发、生产和商业化的独家权利。本公司董事会欣然宣布，本公司已就RC148的独家授权许可协议从艾伯维收到6.5亿美元的首付款。目前双方的合作进展顺利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK1574","09995","BK1583","LU2488822045.USD","LU1064131003.USD","LU2328871848.SGD","LU1969619763.USD","BK0239","688331","LU1064130708.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627540852","title":"港股创新药板块午后持续走高，荣昌生物涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627540852","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627540852?lang=zh_cn&edition=full","pubTime":"2026-04-15 13:10","pubTimestamp":1776229832,"startTime":"0","endTime":"0","summary":"4月15日，港股创新药板块午后持续走高，荣昌生物涨近10%，君实生物涨超5%，诺诚健华、信达生物、复星医药跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705735216.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705735216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU2148510915.USD","BK0239","159992","LU1969619763.USD","688331","LU2328871848.SGD","BK1583","06978","LU2488822045.USD","LU1064130708.USD","09995","BK4588","VXUS","BK4585","BK1161","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627349433","title":"4月13日荣昌生物涨7.98%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627349433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627349433?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:13","pubTimestamp":1776067998,"startTime":"0","endTime":"0","summary":"证券之星消息，4月13日荣昌生物涨7.98%，收盘报146.29元，换手率7.54%，成交量12.3万手，成交额17.51亿元。重仓荣昌生物的前十大公募基金请见下表：该股最近90天内共有10家机构给出评级，买入评级10家；过去90天内机构目标均价为148.5。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共48家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300020025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","LU2488822045.USD","09995","160916","LU1969619763.USD","LU2148510915.USD","BK0239","LU1064131003.USD","BK1574","688331","BK1161","BK1583","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627348834","title":"港股异动 | 荣昌生物(09995)涨超4% 维迪西妥单抗一线治疗HER2表达尿路上皮癌获批国内上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2627348834","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627348834?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:02","pubTimestamp":1776045779,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物(09995)涨超4%，截至发稿，涨4.43%，报110.7港元，成交额2.35亿港元。消息面上，4月10日，荣昌生物宣布，公司自主研发的抗体偶联（ADC）药物维迪西妥单抗（RC48，爱地希®）一项新适应症获国家药品监督管理局正式批准上市，用于联合特瑞普利单抗治疗HER2表达的局部晚期或转移性尿路上皮癌患者，HER2表达定义为HER2免疫组织化学检查结果为1+、2+或3+。荣昌生物表示，这标志着维迪西妥单抗的治疗范围从后线成功拓展至一线，为中国HER2表达晚期尿路上皮癌患者带来了全新的治疗选择，也成为全球首个获批一线治疗晚期尿路上皮癌的HER2-ADC药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09995","BK4585","BK1161","IPOS","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","LU2488822045.USD","688331","BK4588","LU2328871848.SGD","BK1583","LU1969619763.USD","BK0239","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627610285","title":"【机构调研记录】九泰基金调研荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2627610285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627610285?lang=zh_cn&edition=full","pubTime":"2026-04-13 08:01","pubTimestamp":1776038472,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月10日披露的机构调研信息，九泰基金近期对1家上市公司进行了调研，相关名单如下：1）荣昌生物 调研纪要：2025年营业收入32.51亿元，同比增长89.36%；综合毛利率87.3%，同比增长6.9个百分点；研发费用12.19亿元，同比下降20.9%；净利润7.1亿元，实现扭亏为盈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300000934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","688331","LU2328871848.SGD","BK1574","LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","09995","LU2488822045.USD","BK0239","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627389104","title":"智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=2627389104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627389104?lang=zh_cn&edition=full","pubTime":"2026-04-13 07:18","pubTimestamp":1776035912,"startTime":"0","endTime":"0","summary":"牌照于今日生效。伊美第三轮谈判已结束 双方存在严重分歧总台记者当地时间12日获悉，伊朗与美国在伊斯兰堡举行的又一轮会谈已结束。伊朗方面消息称，伊朗与美国代表团在谈判中仍存在一些严重分歧。美伊谈判21小时未达成协议。盛宝银行首席投资策略师 Charu Chanana 表示，美伊谈判无果而终是一次倒退。美英担忧 AI 暴露金融业漏洞Anthropic 发布 AI 模型 Mythos 预览版，美国政府日前召集一批银行高管紧急开会，讨论相关问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7d08dbda469a470286c6f9b045c09156","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06088","NVDA","BK1556","BK1500","CRCA","06185","09995","601869","HSBC","BK4585","LU1791807156.HKD","ICRC","06166","BK1574","BK1583","LU1861217088.USD","06869","BK1596","WFC","LU0106831901.USD","C","00005","BK1161","BK1228","CCUP","LU1861220207.SGD","300748","LU2328871848.SGD","01729","603083","CRCG","01773","AMZN","LU1861559042.SGD","06960","BK4023","CRCD","LU1969619763.USD","688331","LU1668664300.SGD","LUMN","06680","03317","AMD","688185","BAC","CRCO","BK4588","LU1861558580.USD","LU2360107671.USD","AVGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191656067","title":"荣昌生物新药维迪西妥单抗获批用于治疗HER2阳性尿路上皮癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191656067","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191656067?lang=zh_cn&edition=full","pubTime":"2026-04-10 22:36","pubTimestamp":1775831783,"startTime":"0","endTime":"0","summary":"荣昌生物制药股份有限公司宣布，其创新药物维迪西妥单抗（Disitamab Vedotin）的新药上市申请已正式获得批准，适应症为HER2表达阳性的尿路上皮癌。这一重要进展为相关患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU2148510915.USD","BK0239","688331","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626192923","title":"荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192923","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626192923?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:28","pubTimestamp":1775820480,"startTime":"0","endTime":"0","summary":"证券日报网讯4月10日，荣昌生物在互动平台回答投资者提问时表示，公司2025年第四季度利润增长主要系公司在第四季度确认了与VorBiopharmaInc.就RC18达成的授权许可首付款收入，该笔收入在第四季度完成相关合同义务履行并确认。同时，核心产品泰它西普、维迪西妥单抗的销售收入亦保持良好增长态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701423440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LU2488822045.USD","09995","BK1574","LU2148510915.USD","LU2328871848.SGD","BK0239","BK1161","LU1064130708.USD","VOR","LU1969619763.USD","688331","LU1064131003.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626193856","title":"荣昌生物：维迪西妥单抗新适应症获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626193856","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626193856?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:56","pubTimestamp":1775811411,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月10日，荣昌生物(688331.SH)公告称，公司近日收到国家药监局核准签发的《药品注册证书》，维迪西妥单抗联合特瑞普利单抗用于治疗HER2表达的局部晚期或转移性尿路上皮癌的新适应症上市申请获得批准。这是维迪西妥单抗在国内获批的第五项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103701182236.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701182236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","09995","BK0239","LU1969619763.USD","LU1064130708.USD","BK1161","LU2328871848.SGD","LU2488822045.USD","BK1574","BK1583","688331","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625936395","title":"荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625936395","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625936395?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:07","pubTimestamp":1775552830,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，荣昌生物报收于141.66元，较前一交易日下跌4.99%，最新总市值为799.64亿元。近日，荣昌生物披露《华泰联合证券有限责任公司关于荣昌生物制药（烟台）股份有限公司2025年度持续督导现场检查报告》。公告显示，华泰联合证券作为保荐机构，于2026年3月31日对荣昌生物2025年度的公司治理、内部控制、信息披露、独立性、募集资金使用、关联交易、对外担保、重大对外投资及经营状况等情况进行了现场检查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700023601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","09995","LU1969619763.USD","LU2328871848.SGD","BK1583","BK0239","LU2488822045.USD","BK1161","BK1574","688331","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625957616","title":"每周股票复盘：荣昌生物（688331）双抗ADC药物获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625957616","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625957616?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:08","pubTimestamp":1775326093,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，荣昌生物报收于149.1元，较上周的123.58元上涨20.65%。本周，荣昌生物4月2日盘中最高价报150.54元，股价触及近一年最高点。本次获批不影响公司近期业绩，后续需完成临床试验并经审批方可上市。华泰联合证券作为保荐机构，于2026年3月31日完成对荣昌生物2025年度持续督导现场检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995","LU2148510915.USD","LU2488822045.USD","LU1064131003.USD","BK0239","BK1161","BK1574","LU1064130708.USD","LU2328871848.SGD","LU1969619763.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624403631","title":"中金：维持荣昌生物(09995)跑赢行业评级 上调目标价至133.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624403631","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624403631?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:38","pubTimestamp":1775183931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑荣昌生物授权合作收入确认节奏，上调2026年净利润由0.34亿元至42.35亿元，并引入2027年净利润预测7.48亿元。考虑RC148国际化研发提速及业绩改善，基于DCF估值，该行维持跑赢行业评级，上调目标价26.8%至133.7港元，较当前股价有21.1%的上行空间。中金主要观点如下：2025年业绩超过该行预期公司公布2025年业绩：收入32.42亿元，同比增长89.55%;归母净利润7.10亿元，实现扭亏为盈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","09995","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624311466","title":"口服减重新突破，每日一粒告别针头！礼来口服GLP1药在美获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624311466","media":"新浪基金","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624311466?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:31","pubTimestamp":1775183460,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局于本周三批准了礼来公司的口服GLP-1药物Foundayo上市，标志着礼来迎来一个重要里程碑，并为进一步测试此类新型减肥药物的市场潜力提供了机会。消息公布后，礼来股价当日盘中上涨超过5%。该每日一次口服药物预计下周一起通过礼来直销平台LillyDirect开始发货，并将很快在各大药房及远程医疗平台上架销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-03/doc-inhtetzf3810120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2361045086.USD","LU2089984988.USD","LU1868837300.USD","LU2896262040.SGD","LU0823416689.USD","LU2264538146.SGD","LU2211815571.USD","LU1069344957.HKD","LU1366192091.USD","BK4516","LU0708995401.HKD","LU0256863811.USD","LU1291159041.SGD","LU1989771016.USD","LU0256863902.USD","LU1548497426.USD","LU0943347566.SGD","SG9999001176.USD","LU0079474960.USD","LU1551013342.USD","LU1267930730.SGD","LU1323610961.USD","LU2236285917.USD","LU0353189763.USD","IE00BN29S564.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0672654240.SGD","LU0689472784.USD","SG9999015986.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRX11.SGD","LU2471134796.USD","GB00BDT5M118.USD","SG9999018865.SGD","LU0882574139.USD","SG9999015952.SGD","688331","BK4585","LU1868836757.USD","LU2237443549.SGD","IE00BFSS8Q28.SGD","IE0001KFT4U8.USD","LU2237443382.USD","LU1127390331.HKD","LU2471134952.CNY","LU2602419157.SGD","LU2023250504.SGD","LU0061475181.USD","IE00BJLML261.HKD","LU0094547139.USD","LU2461242641.AUD","LU1917777945.USD","LU0006306889.USD","LU0058720904.USD","LU2237443978.SGD","LU0432979614.USD","IE00B1BXHZ80.USD","LU1093756168.USD","ELIS","LU0203202063.USD","LU0456855351.SGD","LU0158827948.USD","LU2357305700.SGD","LU1988902786.USD","LU0109391861.USD","SG9999014880.SGD","LU2552382215.SGD","LU0234572021.USD","LU2168563687.JPY","LU0122379950.USD","LU0096364046.USD","LU1712237335.SGD","LU2417539215.USD","LU2756315664.SGD","IE00B1XK9C88.USD","LU2491049909.HKD","IE00BWXC8680.SGD","LU0198837287.USD","LLYX","LU0385154629.USD","LU2361044865.SGD","LU2471134879.HKD","BK4599","IE00B4JS1V06.HKD","IE00BJJMRZ35.SGD","LU1804176565.USD","LU2168564149.EUR","LU0882574055.USD","LU0683600562.USD","LU2462157665.USD","SGXZ99366536.SGD","LU0106261372.USD","LU0210536198.USD","IE00BJT1NW94.SGD","LU1551013425.SGD","LU2746668461.USD","SGXZ81514606.USD","LU2168564222.USD","LU2756315318.SGD","LU0466842654.USD","01066","IE0004445239.USD","LLY","LU0354030511.USD","LLII","LU0640476718.USD","LU2089284900.SGD","LU2087625088.SGD","LU2168564495.EUR","LLYZ","LU2237443895.HKD","SG9999014914.USD","BK4581","LU1280957306.USD","LU0471298694.HKD","IE00BK4W5M84.HKD","LU0323591593.USD","LU1061106388.HKD","LU2750360997.AUD","LU0417517546.SGD","LU1064131342.USD","09995","LU2750360641.GBP","BK4588","LU2237443622.USD","LU2237443465.HKD","LU0889565916.HKD","ELIL","SG9999015978.USD","SG9999018857.SGD","LU2456880835.USD","LU2213496289.HKD","LU2265009873.SGD","LU2023250330.USD","IE00BKPKM429.USD","LU0114720955.EUR","LU2491050071.SGD","LU1093756325.SGD","LU1868837136.USD","LU0320765059.SGD","LU0820562030.AUD","BK4007","LU0097036916.USD","LU2089283258.USD","LU2491050154.USD","LU0471298777.SGD","LU1023059063.AUD","IE00BKDWB100.SGD","LU1868836591.USD","LU2237438978.USD","LU1623119135.USD","LU0354030438.USD","SGXZ57979304.SGD","LU1629891620.HKD","LU1814569148.SGD","LU2168564065.EUR","LU2468319806.SGD","BK4534","LU0320765992.SGD","IE0002141913.USD","LU2552382132.HKD","IE00BFSS7M15.SGD","LU0238689110.USD","SG9999014906.USD","LU0820561818.USD","LU1974910355.USD","IE00BK4W5L77.USD","BK4533","IE00B7KXQ091.USD","LU1035775433.USD","LU2471134523.USD","LU2108987350.USD","LU0787776722.HKD","IE00BJJMRY28.SGD","LU2360106947.USD","SG9999017495.SGD","IE00B775H168.HKD","LU0266013472.USD","LU2106854487.HKD","LU0820561909.HKD","SGXZ51526630.SGD","LU0109394709.USD","LU2063271972.USD","SG9999014898.SGD","LU0225283273.USD","SG9999013999.USD","LU2361044949.HKD","IE0005OL40V9.USD","LU0823434583.USD","LU2112291526.USD","LU1720051017.SGD","LU0158827781.USD","LU0786609619.USD","LU2271345857.HKD","LU1983299246.USD","LU2746668974.SGD","LU2023251221.USD","LU1057294990.SGD","SG9999001176.SGD","LU2324357040.USD","SGXZ31699556.SGD","LU0353189680.USD","LU0823434740.USD","IE00B4R5TH58.HKD","LU0316494557.USD","SHWGY","IE0004445015.USD","LU2552382058.USD","LU0964807845.USD","LU2028103732.USD","SG9999015945.SGD","LU1868836914.USD","LU1720051108.HKD","LU1232071149.USD","LU0203201768.USD","LU2111349929.HKD","LU1145028129.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624024295","title":"荣昌生物（688331）披露双抗ADC药物RC288获临床试验批准通知书，4月2日股价上涨4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624024295","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624024295?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:02","pubTimestamp":1775138548,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，荣昌生物报收于149.93元，较前一交易日上涨4.12%，最新总市值为846.32亿元。荣昌生物制药（烟台）股份有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的双抗ADC药物注射用RC288单药治疗局部晚期不可切除或转移性恶性实体肿瘤的I/Ⅱa期临床试验获得批准。RC288是一款同时靶向PSMA和B7H3的双特异性ADC，采用新一代偶联及毒素技术开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200041675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","BK0239","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","BK1574","LU1064130708.USD","BK1161","09995","LU2148510915.USD","BK1583","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624780521","title":"盈利转正、BD落地，荣昌生物全球化布局走到哪一步？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624780521","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624780521?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:10","pubTimestamp":1775099411,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明实习生蒋雨桐受益于核心产品商业化放量，叠加BD（商务拓展）授权收入贡献，荣昌生物（688331.SH；09995.HK）交出近三年来最优业绩答卷。2025年年报显示，期内公司实现营业收入32.51亿元，同比上涨89.36%；归母净利润扭亏为盈，达7.1亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693148433.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693148433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09995","BK1161","BK0239","LU1969619763.USD","BK1583","LU2328871848.SGD","LU1064131003.USD","LU2148510915.USD","BK1574","LU1064130708.USD","LU2488822045.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163264510","title":"荣昌生物双特异性抗体偶联药物RC288注射液获中国药监局临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1163264510","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163264510?lang=zh_cn&edition=full","pubTime":"2026-04-01 22:30","pubTimestamp":1775053845,"startTime":"0","endTime":"0","summary":"荣昌生物近日宣布，其研发的双特异性抗体偶联药物（Bispecific ADC）RC288注射液已获得中国国家药品监督管理局（NMPA）的临床试验批准。这一进展标志着公司在创新药物研发领域取得重要突破。\nRC288作为一款双特异性抗体药物偶联物，结合了抗体靶向性和细胞毒性药物的杀伤力，有望为相关疾病治疗提供新的解决方案。此次获批进入临床阶段，将为后续研究奠定基础。\n公司表示，将积极推进RC288的临床试验工作，探索其在适应症中的安全性和有效性。该进展也体现了中国在生物医药领域的创新能力和监管支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU2148510915.USD","BK0239","LU2488822045.USD","688331","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624596896","title":"荣昌生物(688331.SH)：双抗ADC药物注射用RC288获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624596896","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624596896?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:45","pubTimestamp":1775033156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的双抗ADC药物RC288单药治疗局部晚期不可切除或转移性恶性实体肿瘤的I/Ⅱa期临床试验获得批准。RC288是一款同时靶向PSMA和B7H3的双特异性ADC，是荣昌生物采用新一代偶联及毒素技术开发的创新药物分子。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","ADC","BK1161","BK0239","LU1969619763.USD","BK1583","BK4080","LU2328871848.SGD","LU1064131003.USD","LU2148510915.USD","BK1574","LU1064130708.USD","BK4231","LU2488822045.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371411","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 指盈亏平衡可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371411","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371411?lang=zh_cn&edition=full","pubTime":"2026-03-31 11:04","pubTimestamp":1774926260,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，2025年，荣昌生物 产品销售收入同比+35.8%至23.07亿元，其中：1）泰它西普销售+42%至13.9 亿元，SLE仍为贡献最大的适应症，肾科和神免快速增长中、未来占比将提升；2）维迪西妥销售+22.5%至 8.8 亿元，UC 适应症贡献约70%，近期获批的乳腺癌伴肝转移有望在2026年带来较大销售贡献。此外，多项BD授权交易推动许可收入达8.95亿元。维持136港元目标价，维持买入评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977831","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776322033664,"stockEarnings":[{"period":"1week","weight":0.0531},{"period":"1month","weight":0.3294},{"period":"3month","weight":0.4204},{"period":"6month","weight":0.5301},{"period":"1year","weight":2.1217},{"period":"ytd","weight":0.9154}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17456人(较上一季度增加4.94%)","perCapita":"9343股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}